Jessica N. Lange¹, Linda Easter¹, Robert Amoroso¹, Debra Benfield¹, Patrick W. Mufarrij², John Knight³, Ross P. Holmes³, Dean G. Assimos³

Canadian Journal of Urology, Vol.20, No.5, pp. 6922-6926, 2013

Abstract Introduction: Certain dietary modifications limit the risk of stone recurrence. Compliance is an important component of dietary therapy for stone prevention, and self-efficacy is an important ingredient of compliance. We developed an internet program to facilitate dietary compliance for stone prevention and performed a pilot study to assess its effectiveness.
Materials and methods: The internet program provides information regarding dietary modifications including increased fluid consumption, limited animal protein, sodium, and oxalate intake, and adequate calcium consumption. Participants record their daily food and fluid intake and receive immediate feedback as to whether they were compliant or not. Five… More >

Elias S. Hyams¹, Brian R. Matlaga¹, Frederick K. Korley²

Canadian Journal of Urology, Vol.19, No.4, pp. 6351-6359, 2012

Abstract Introduction: The emergency department (ED) is a common setting for evaluation of patients with urolithiasis based on acute symptoms and a propensity for recurrent disease. We sought to characterize practice patterns in the emergency treatment of stone disease, and to identify potential disparities in care based on non-medical factors.
Materials and methods: We performed a cross-sectional analysis of ED visits using the National Hospital Ambulatory Medical Care Survey from 2005-2009. Visits with a diagnosis of urolithiasis were identified. The associations between patient, provider, and institutional characteristics were analyzed with regard to timing of clinical assessment, use of… More >

Carlos H. F. Chan, Assaad El-Hakim, Sero Andonian

Canadian Journal of Urology, Vol.17, No.2, pp. 5127-5130, 2010

Abstract Introduction: Matrix stones are rare types of urinary calculi composed of mucoproteins and mucopolysaccharides. Since isolated flank pain may be the only presenting symptom and routine radiographic studies are usually non-informative, diagnosis of such urinary calculi represents a clinical challenge. Traditionally, these matrix stones have been managed by either open pyelolithotomy or percutaneous nephrolithotomy (PCNL). Ureteroscopic management of a patient with matrix renal stones and review of literature is presented.
Case report: A 34-year-old woman presented with chronic right flank pain. Abdominal ultrasound found a 5.3 cm heterogeneous right renal pelvic mass with 9.7 mm stone. CT… More >

Luke T. Lavallee, J. P. McCarthy, Richard W. Norman

Canadian Journal of Urology, Vol.15, No.1, pp. 3928-3929, 2008

Abstract We report upon a patient who underwent a subtotal colectomy 2 years prior to presenting for a percutaneous nephrolithotomy of a large stone in the left renal pelvis. At the time of surgery, a non-absorbable suture was found embedded in the stone. Both stone and suture were removed percutaneously. More >

K. C. Hayes, K. Bassett-Spiers, R. Das, K. D. Ethans, C. Kagan, J. L. K. Kramer, T. Linsenmeyer, K. N. Moore, H. Razvi, G. Reid, J. S. Walter, J. W. L. Wilson

Canadian Journal of Urology, Vol.14, No.1, pp. 3416-3423, 2007

Abstract Objective: A multidisciplinary panel of experts from Canada and the United States was convened by the Ontario Neurotrauma Foundation (ONF) to establish research priorities in the area of urological care following spinal cord injury (SCI).
Design: The panel reviewed a synthesis of published literature in five areas of urology, identified emerging opportunities in the private and public sector, and used a modified Delphi approach to reach consensus on priorities for funding.
Results: The panel recommendations included: clinical trials of the safety and efficacy of M3 receptor specific anti-muscarinic agents for bladder hyperactivity in SCI patients; development and… More >

Thai T. Nguyen, Bernard Fallon, Howard N. Winfield

Canadian Journal of Urology, Vol.12, No.4, pp. 2769-2771, 2005

Abstract Guaifenesin is a commonly used expectorant whose use may lead to the occasional formation of guaifenesin urinary stones. We herein describe a patient who was taking 2400 mg Guaifenesin per day as part of his treatment for asthma. He had a past history of a guaifenesin stone removed ureteroscopically. His current presentation was with a 9 mm by 6 mm stone in the upper left ureter, seen on CT scan, and treated initially with a ureteral stent and hydration. After 3 weeks, the stone had disappeared, as confirmed by repeat CT scan. The genesis and More >